109 related articles for article (PubMed ID: 23870475)
1. Expression and significance of p53 and mdm2 in patients with leukoplakia cancer.
Cui JJ; Han XL; Wang WM
Asian Pac J Trop Med; 2013 Oct; 6(10):831-4. PubMed ID: 23870475
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer.
Misra C; Majumder M; Bajaj S; Ghosh S; Roy B; Roychoudhury S
Mol Carcinog; 2009 Sep; 48(9):790-800. PubMed ID: 19204927
[TBL] [Abstract][Full Text] [Related]
3. [Expression and its relationship of murine double minute 2 and P53 protein in oral leukoplakia and squamous cell carcinoma].
Han BF; Wu PF; Pan J; Li Y; Li LJ
Hua Xi Kou Qiang Yi Xue Za Zhi; 2011 Feb; 29(1):79-82. PubMed ID: 21427907
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
[TBL] [Abstract][Full Text] [Related]
6. P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.
Jiang Z; Xu W; Dan G; Liu Y; Xiong J
Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
[TBL] [Abstract][Full Text] [Related]
7. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
8. Translational approach utilizing COX-2, p53, and MDM2 expressions in malignant transformation of oral submucous fibrosis.
Patel PN; Thennavan A; Sen S; Chandrashekar C; Radhakrishnan R
J Oral Sci; 2015 Sep; 57(3):169-76. PubMed ID: 26369479
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
Soufla G; Baritaki S; Sifakis S; Zafiropoulos A; Spandidos DA
Int J Biol Markers; 2005; 20(1):18-27. PubMed ID: 15832769
[TBL] [Abstract][Full Text] [Related]
10. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
11. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia.
Wood MW; Medina JE; Thompson GC; Houck JR; Min KW
Otolaryngol Head Neck Surg; 1994 Dec; 111(6):758-63. PubMed ID: 7527509
[TBL] [Abstract][Full Text] [Related]
13. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jul; 36(7):5425-32. PubMed ID: 25672611
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
15. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
16. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
[TBL] [Abstract][Full Text] [Related]
17. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.
Manfredi JJ
Genes Dev; 2010 Aug; 24(15):1580-9. PubMed ID: 20679392
[TBL] [Abstract][Full Text] [Related]
18. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of PDCD5 and p53 in oral leukoplakia and oral squamous cell carcinoma].
Zhao XY; Liu HW; Wei MJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):429-32. PubMed ID: 16086069
[TBL] [Abstract][Full Text] [Related]
20. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
